Commentary|Podcasts|October 3, 2024

Dr Rick Chapman Discusses Key Insights From the Center’s Rare Disease Project

On this episode of Managed Care Cast, we're talking with the chief science officer of the Center for Innovation & Value Research about key insights from its Rare Disease project.

On this episode of Managed Care Cast, we're talking with Rick Chapman, PhD, chief science officer of the Center for Innovation & Value Research, formerly known as the Innovation and Value Initiative (IVI).

We discussed the Center's Rare Disease project, including the primary goals, key discoveries from phase 1, and what to expect moving forward.

Listen above or on one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Dr Rick Chapman Discusses Key Insights From the Center’s Rare Disease Project

Related Content

Specialty Pharmacy Drives Advanced Therapy Access: Fran Gregory, PharmD

The Combination Changing the Neoadjuvant Calculus in Breast Cancer: Coral Omene, MD, PhD

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

Cancer, Trauma, and Healing the Whole Person

Cardiorenal Benefits of SGLT2 Inhibitors Beyond Diabetes: Sandra Chaparro, MD

Trending on AJMC

EHA 2026 Late Breakers Deliver Practice-Shifting Phase 3 Data and Novel CAR T Approaches Across Hematology

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Teclistamab Outperforms Len/Dex in High-Risk Smoldering Myeloma With Higher CR Rate, PFS: Omar Nadeem, MD

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered